EXPOSÉ: DEA's Marijuana Licensing Scheme Exposed
MMJ BioPharma Cultivation's case reveals a contradiction in the DEA's rules, blocking FDA-approved cannabis medicine.
Newly uncovered DEA agreements confirm that the agency's own rules make it impossible for any company to legally produce pharmaceutical-grade cannabis for FDA-authorized clinical research.
A recently disclosed memorandum of understanding between the DEA and a registered marijuana cultivator has revealed the DEA's fatal flaw at the heart of America's cannabis research policy.
This flaw has paralyzed legitimate science for nearly a decade, proving MMJ BioPharma Cultivation's case.
Author's summary: DEA's rules hinder cannabis research.
More News
- Battlefield 6 REDSEC battle royale to officially launch soon
- Man Utd Failed With £50 Million Mbeumo Alternative
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups
- Rutgers Health and University Hospital Break Ground on First Phase of Sweeping Newark Campus Redevelopment
- West Indies ease past Bangladesh in first T20I
- How to Design and Install the Best Ventilation System for Your Cooking Needs | NorthPennNow
- Budget jitters see construction forecasts plummet
- 5 members of the 2025 Yankees make list of top 50 free agents
- Three resilient UK multinationals global managers are excited about | Trustnet
- Sweden’s still ahead in the preparedness game — and now it means business